Draig Therapeutics has been backed by a number of global venture capital firms to help commercialise its pioneering therapies ...

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on ...

Controlling weight and cardiovascular risk factors is paramount in type 2 diabetes management; however, the definition and feasibility of remission warrant closer examination. Type 2 diabetes ...

Q4 2025 Management View President and CEO Shawn K. Singh highlighted that Vistagen is advancing a pipeline of five ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

A breakthrough in breast cancer research is showing promising signs in the development of a vaccine for the disease. Anixa Biosciences, Inc. is working with the Cleveland Clinic to ...

The researchers hypothesized that sildenafil would increase oxygen flow to the placenta and to the unborn fetus, reducing ...

The International Agency for Research on Cancer forecasts over 35 million new cancer cases in 2050 globally. The growing ...

While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play ...

Diversity in clinical trials can positively impact patient care and outcomes, particularly among minority populations, Anita ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...